Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Revelation Biosciences Inc. (REVB:NASDAQ), powered by AI.
Revelation Biosciences Inc. is currently trading at $1.00. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Revelation Biosciences Inc. on Alpha Lenz.
Revelation Biosciences Inc.'s P/E ratio is -0.1.
“Revelation Biosciences Inc. trades at a P/E of -0.1 (undervalued) with modest ROE of -131.4%.”
Ask for details →Revelation Biosciences Inc. is a biotechnology company focused on developing diagnostic and therapeutic products to address respiratory and infectious diseases. Their primary function is to innovate in the field of healthcare with novel solutions that can detect and combat prevalent health threats. Notably, Revelation Biosciences is involved in creating point-of-care diagnostic tests that aim to quickly and efficiently identify infections, enabling timely and informed medical decisions. The company also pursues therapeutic development to improve treatment outcomes for patients suffering from respiratory ailments. Within the financial market, Revelation Biosciences contributes to the healthcare and biotech sectors, representing the intersection of technology and medicine to address critical health challenges. With a commitment to research and development, Revelation Biosciences is a key player in improving diagnostic and therapeutic approaches, thus enhancing healthcare delivery and patient care globally.
“Revelation Biosciences Inc. trades at a P/E of -0.1 (undervalued) with modest ROE of -131.4%.”
Ask for details →Revelation Biosciences Inc. (ticker: REVB) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 8 employees. Market cap is $618,488.
The current price is $0.996 with a P/E ratio of -0.07x and P/B of 0.07x.
ROE is -131.38%.